Results 121 to 130 of about 5,230,993 (373)
Heliyon, 2019 Anxiety disorders, depression and pain are highly prevalent pathologies. Their pharmacotherapy is associated with unwanted side effects; hence there is a clinical need to develop more effective drugs with fewer adverse reactions.Chalcones are one of the ...
Josefina Higgs +8 more
doaj
iScience, 2021 Summary: The 2019 coronavirus disease (COVID-19) became a worldwide pandemic with currently no approved effective antiviral drug. Flux balance analysis (FBA) is an efficient method to analyze metabolic networks.
Ali Kishk +2 more
doaj
A Validated Model to Predict Severe Weight Loss in Amyotrophic Lateral Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Severe weight loss in amyotrophic lateral sclerosis (ALS) is common, multifactorial, and associated with shortened survival. Using longitudinal weight data from over 6000 patients with ALS across three cohorts, we built an accelerated failure time model to predict the risk of future severe (≥ 10%) weight loss using five single‐timepoint ...
David G. Lester +4 more
wiley +1 more source
Heliyon, 2018 In an effort to discover an effective and selective antitumour agent, synthesis and anti-cancer potential of 4-(pyridin-4-yl)-6-(thiophen-2-yl) pyrimidin-2(1H)-one (SK-25), which has been reported earlier by us with significant cytotoxicity towards ...
Dinesh Kumar +11 more
doaj
Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji +9 more
wiley +1 more source
Clinical Trials, Innovation and Approaches to Ambidexterity in Pharmaceutical Startup Companies [PDF]
, 2013 The author investigated how the clinical trial process affected innovation in phar- maceutical start-up firms. An inductive qualitative case study methodology was uti- lized to investigate 3 pharmaceutical start-up firms who were conducting late stage ...
Heikki, Sørum
core
Digital Activity Markers in Chronic Inflammatory Demyelinating Polyneuropathy
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To evaluate the utility of smartwatch and smartphone‐based activity metrics for assessing disease severity and quality of life in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Methods In the electronic monitoring of disease activity in patients with CIDP (EMDA‐CIDP) trial, we performed a prospective ...
Lars Masanneck +15 more
wiley +1 more source
Early Academis Science and the Birth of Industrial Research Laboratories in the U.S. Pharmaceutical Industry [PDF]
The establishment and growth of industrial research laboratories is one of the key organizational innovations affecting technological progress in the United States in the 20th century.
Jeffrey L. Furman, Megan MacGarvie
core
Transforming Pharmacy and Pharmaceutical Sciences Education in the Context of Workforce Development [PDF]
, 2017 KEY MESSAGES: 1.1 The continued development of pharmacy services and the pharmaceutical sciences relies on a well educated, competent, sufficient and well distributed pharmaceutical workforce. 1.2 There is no workforce without education.
Bader, L +3 more
core
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective The Apolipoprotein (APOE) ε4 allele is the strongest genetic risk factor for late‐onset Alzheimer's disease (AD); however, many ε4 carriers remain cognitively intact into old age. Leveraging plasma neuron‐derived extracellular vesicles (NDEVs), we sought to identify biomarkers of cognitive resilience and their interplay with APOE ...
Apostolos Manolopoulos +17 more
wiley +1 more source